Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Vascular Dysfunction in Human Obesity Hypertension
NCT01983462 · Gary L. Pierce · PHASE2 · terminated · last registry update 2023-04-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Funding expired” | – | Registry record, Gary L. Pierce |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ADRA2A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-12-08Also stopped (terminated): University of Toronto, a drug against ADRA2A (NCT03409185)
- 2023-10-25Phase 3 first posted: Humanitas Clinical and Research Center, Cannabidiol and β-Caryophyllene Patch (NCT06099171)
- 2023-09-28Results posted on the registry: University of Michigan, carbidopa (NCT04325503)
- 2023-08-21Results posted on the registry: Alcon Research, a drug against ADRA2A (NCT03316885)
- 2023-07-14Phase 3 first posted: Milton S. Hershey Medical Center, Oxymetazoline 0.1% (Pf) Oph Soln Ud (NCT05945615)
- 2023-05-22Results posted on the registry: New York State Psychiatric Institute, L-DOPA + Placebo Oral Tablet (NCT03761030)
- 2023-05-22Also stopped (terminated): New York State Psychiatric Institute, L-DOPA + Placebo Oral Tablet (NCT03761030)
- 2023-03-13Phase 3 first posted: DoCare Pharmaceutial Technology Co.,Ltd, Zihua Wenfei Zhisou Granule + Placebo (NCT05764668)
- 2023-02-22Phase 3 first posted: Ain Shams University, Epinephrine Inhalation Solution (NCT05738564)
- 2023-02-13Phase 3 first posted: Ain Shams University, Ephedrine + Rocuronium 0.6 (NCT05725031)
- 2022-11-18Results posted on the registry: AbbVie, ABBV-951 + Placebo for Levodopa/Carbidopa (LD/CD) (NCT04380142)
- 2022-10-31Also stopped (withdrawn): Azidus Brasil, Loratadine + Pseudoephedrine sulfate (NCT01055756)
- 2022-10-21Results posted on the registry: Vanderbilt University Medical Center, a drug against ADRA2A (NCT04076072)
- 2022-10-17Also stopped (suspended): Jessica M D'Amico, 5HTP + L-DOPA (NCT04000919)
- 2022-08-11Phase 3 first posted: Brugmann University Hospital, Ephedrine + Norepinephrine (NCT05497700)
- 2022-07-22Also stopped (suspended): Beijing Chao Yang Hospital, Montelukast (NCT02655562)
- 2022-07-05Results posted on the registry: University Hospitals Cleveland Medical Center, Vasoconstrictor Agents + Additional anesthesia (NCT01866657)
- 2022-07-05Also stopped (terminated): University Hospitals Cleveland Medical Center, Vasoconstrictor Agents + Additional anesthesia (NCT01866657)
- 2022-06-15Results posted on the registry: USWM, LLC (dba US WorldMeds), Lofexidine (granules for reconstitution) + LUCEMYRA (lofexidine) tablets (NCT04188730)
- 2022-06-02Results posted on the registry: Northwestern University, Ephedrine + Phenylephrine (NCT00458003)
- 2022-05-24Also stopped (withdrawn): YingHsuanTai, Dexamethasone 8 mg + Placebo (0.9% sodium chloride) (NCT05016076)
- 2022-04-18Also stopped (terminated): Shahid Beheshti University, a drug against ADRA2A (NCT03454334)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision